Objective To investigate the efficacy of goserelin combined with bicalutamide in the treatment of advanced prostate cancer (PCa) and its effect on immune function and quality of life. Methods From January 2016 to September 2018, 94 patients with advanced PCa admitted to our hospital were divided into control group (47 cases) and observation group (47 cases) according to random number table method. The control group was treated intermittently with goserelin combined with bicalutamide, while the observation group was treated intermittently with goserelin combined with bicalutamide. The changes of serum prostate specific antigen (PSA), free PSA (F-PSA) levels and immune function indexes (CD3+, CD4+, CD8+, CD4+/CD8+) were compared between the two groups before treatment and nine months after treatment. The clinical efficacy and adverse reactions of the two groups were observed, and the quality of life before and after treatment for nine months were observed. Results The total effective rate of the observation group (87.2% vs. 68.1%) after treatment was significantly better than that of the control group (P<0.05). The levels of serum PSA and F-PSA in the observation group and the control group after treatment were significantly lower than those before treatment (P<0.05), while there were no significant difference in the levels of serum PSA[（4.63±1.08) ng/mL vs. (5.26±1.24) ng/mL] and F-PSA[(1.04±0.20) ng/mL vs. (1.18±0.25) ng/mL]between the observation group and the control group after treatment (P>0.05). The levels of CD3+, CD4+ and CD4+/CD8+ in the observation group and the control group were significantly higher than those before treatment (P<0.05), while the levels of CD8+ in the two groups were significantly lower than those before treatment (P<0.05). The scores of sexual function, urinary function, intestinal function and hormone function in observation group and control group after treatment were significantly lower than those before treatment (P<0.05). After treatment, the scores of sexual function [(82.64±4.37)score vs.(76.40±4.25)score], urinary function [(38.74±4.06) score vs. (29.62±3.58)] score, intestinal function [(86.50±8.20) score vs. (78.35±7.42)score], and hormone function [(76.52±7.48)score vs. (66.40±6.82)score] in the observation group were significantly higher than those in the control group (P<0.05). The incidence of adverse reactions in the observation group (19.1% vs. 44.7%) was significantly lower than that in the control group(P<0.05). Conclusions The clinical efficacy of intermittent administration of goserelin combined with bicalutamide in the treatment of advanced PCa is significantly better than that of continuous administration, which can improve the quality of life of patients and reduce the incidence of adverse reactions.
